Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

Recruiting now · Phase 2

Conditions studied: Hodgkin Lymphoma, Adult

In brief

The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma

Key facts

Study ID

NCT06984146

Run by

National Medical Research Radiological Centre of the Ministry of Health of Russia

People needed

54

Starts

2025-04-15

Expected to finish

2029-01-01

Last updated by the study team

2025-11-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly-diagnosed histologically verified advanced stage (IIB-IV as per GHSG) classic Hodgkin lymphoma
• No past history of autoimmune disease
• Age > 18 years
• Ejection fraction > 50%
• ECOG 0-4

You may not qualify if…

• Organ failure (e.g. creatinine > 2x ULN; ALT or AST > 5x ULN; bilirubin > 2x ULN; hemodynamic instability; respiratory failure > Grade 1)
• Uncontrolled infection
• Pregnancy
• Inability to sign informed consent

Where it is running

• P. Hertsen Moscow Oncology Research Institute (MORI) for administrative and economic work - the branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation — Moscow, Russia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.